News
OTLC
0.036
NaN%
--
Weekly Report: what happened at OTLC last week (0318-0322)?
Weekly Report · 3d ago
Linkage of Cancer and Lupus in Gliomas Patients
Oncotelic Therapeutics, Inc. Announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA levels in low-grade gliomas. The study is published in the Journal of Glioma Research and Therapy.
Barchart · 3d ago
Weekly Report: what happened at OTLC last week (0311-0315)?
Weekly Report · 03/18 12:02
Weekly Report: what happened at OTLC last week (0304-0308)?
Weekly Report · 03/11 11:58
Weekly Report: what happened at OTLC last week (0226-0301)?
Weekly Report · 03/04 12:01
Invitation to Participate in STOP-PC Clinical Trial
Barchart · 03/04 07:17
Weekly Report: what happened at OTLC last week (0219-0223)?
Weekly Report · 02/26 12:19
Weekly Report: what happened at OTLC last week (0212-0216)?
Weekly Report · 02/19 12:22
Weekly Report: what happened at OTLC last week (0205-0209)?
Weekly Report · 02/12 12:08
Weekly Report: what happened at OTLC last week (0129-0202)?
Weekly Report · 02/05 12:20
Oncotelic Therapeutics Secures Funds Through Equity Sales
TipRanks · 02/03 09:38
Oncotelic Therapeutics Strikes Material Definitive Legal Agreement
TipRanks · 02/03 09:38
Weekly Report: what happened at OTLC last week (0122-0126)?
Weekly Report · 01/29 12:03
Weekly Report: what happened at OTLC last week (0115-0119)?
Weekly Report · 01/22 12:09
Weekly Report: what happened at OTLC last week (0108-0112)?
Weekly Report · 01/15 12:04
Weekly Report: what happened at OTLC last week (0101-0105)?
Weekly Report · 01/08 12:09
Weekly Report: what happened at OTLC last week (1225-1229)?
Weekly Report · 01/01 12:02
Weekly Report: what happened at OTLC last week (1218-1222)?
Weekly Report · 12/25/2023 12:18
Weekly Report: what happened at OTLC last week (1211-1215)?
Weekly Report · 12/18/2023 12:27
Weekly Report: what happened at OTLC last week (1204-1208)?
Weekly Report · 12/11/2023 12:19
More
Webull provides a variety of real-time OTLC stock news. You can receive the latest news about Oncotelic Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLC
Oncotelic Therapeutics, Inc., formerly Mateon Therapeutics, Inc., is an immuno-oncology company. The Company is engaged in development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. The ArtiVeda/ArtiShield is a derivative from the plant Artemisia. Its immuno-oncology drug candidate, OT-101, is developed for the treatment of solid tumors with focus on brain cancer in adult and diffuse intrinsic pontine glioma (DIPG) in children. The Company’s OT-101 completed phase II for pancreatic cancer, melanoma, and glioblastoma. Its CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. The OXi4503 is developed for the treatment of liquid tumors with focus on childhood leukemia.